Staphylococcus aureus and CCR5: Unveiling commonalities in host-pathogen interactions and potential treatment strategies

Future Microbiology

Volumn 8, Issue 4, 2013, Pages 425-428

  Alonzo, Francis ^a   Torres, Victor J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CCR5; leukotoxins; LukED; pathogen evolution; Staphylococcus aureus; therapeutics

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INTERLEUKIN 17; LEUKOTOXIN;

ANTIGEN PRESENTING CELL; CELL DEATH; CELL MEMBRANE; CYTOTOXICITY; DENDRITIC CELL; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; TH1 CELL; TH17 CELL; YERSINIA PESTIS;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; RECEPTORS, CCR5; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 84875741718     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.12     Document Type: Review

References (20)

1. Foster TJ. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3(12), 948-958 (2005).
2. Alonzo F III, Kozhaya L, Rawlings SA et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 493(7430), 51-55 (2013).
3. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381(6584), 661-666 (1996).
4. Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381(6584), 667-673 (1996).
5. Doranz BJ, Rucker J, Yi Y et al. A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85(7), 1149-1158 (1996).
6. Lalani AS, Masters J, Zeng W et al. Use of chemokine receptors by poxviruses. Science 286(5446), 1968-1971 (1999).
7. Rahbar R, Murooka TT, Fish EN. Role for CCR5 in dissemination of vaccinia virus in vivo. J. Virol. 83(5), 2226-2236 (2009).
8. Aliberti J, Valenzuela JG, Carruthers VB et al. Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat. Immunol. 4(5), 485-490 (2003).
9. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86(3), 367-377 (1996).
10. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-2011;5 chemokine receptor gene. Nature 382(6593), 722-725 (1996).
11. Stephens JC, Reich DE, Goldstein DB et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62(6), 1507-1515 (1998).
12. Mecsas J, Franklin G, Kuziel WA, Brubaker RR, Falkow S, Mosier DE. Evolutionary genetics: CCR5 mutation and plague protection. Nature 427(6975), 606 (2004).
13. Ghorban K, Dadmanesh M, Hassanshahi G et al. Is the CCR5 Delta 32 mutation associated with immune system-related diseases? Inflammation doi:10.1007/s1-753- 012-9585-8 (2012) (Epub ahead of print).
14. Hutter G, Nowak D, Mossner M et al. Long-2011;term control of HIV by CCR5 D32/D32 stem-cell transplantation. N. Engl. J. Med. 360(7), 692-698 (2009).
15. Klein RS. A moving target: the multiple roles of CCR5 in infectious diseases. J. Infect. Dis. 197(2), 183-186 (2008).
16. Lim JK, McDermott DH, Lisco A et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J. Infect. Dis. 201(2), 178-185 (2010).
17. Lin L, Ibrahim AS, Xu X et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5(12), e1000703 (2009).
18. Zielinski CE, Mele F, Aschenbrenner D et al. Pathogen-induced human Th17 cells produce IFN-g or IL-10 and are regulated by IL-1b. Nature 484(7395), 514-518 (2012).
19. Cho JS, Pietras EM, Garcia NC et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 120(5), 1762-1773 (2010).
20. Alonzo F 3rd, Benson MA, Chen J, Novick RP, Shopsin B, Torres VJ. Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol. Microbiol. 83(2), 423-435 (2012).